BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17597706)

  • 1. Risk factors and hormone-receptor status: epidemiology, risk-prediction models and treatment implications for breast cancer.
    Chen WY; Colditz GA
    Nat Clin Pract Oncol; 2007 Jul; 4(7):415-23. PubMed ID: 17597706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting risk of breast cancer in postmenopausal women by hormone receptor status.
    Chlebowski RT; Anderson GL; Lane DS; Aragaki AK; Rohan T; Yasmeen S; Sarto G; Rosenberg CA; Hubbell FA;
    J Natl Cancer Inst; 2007 Nov; 99(22):1695-705. PubMed ID: 18000216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
    Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
    J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progestagens use before menopause and breast cancer risk according to histology and hormone receptors.
    Fabre A; Fournier A; Mesrine S; Gompel A; Desreux J; Berrino F; Boutron-Ruault MC; Romieu I; Clavel-Chapelon F
    Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2723-8. PubMed ID: 18843015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
    Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
    Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA; El-Sayed ME; Green AR; Paish EC; Powe DG; Gee J; Nicholson RI; Lee AH; Robertson JF; Ellis IO
    J Clin Oncol; 2007 Oct; 25(30):4772-8. PubMed ID: 17876012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alcohol and breast cancer risk defined by estrogen and progesterone receptor status: a case-control study.
    Deandrea S; Talamini R; Foschi R; Montella M; Dal Maso L; Falcini F; La Vecchia C; Franceschi S; Negri E
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):2025-8. PubMed ID: 18708394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen and progesterone receptor status in primary breast cancer--a study of 11,273 patients from the year 1990 to 2002.
    Vrbanec D; Petricević B
    Coll Antropol; 2007 Jun; 31(2):535-40. PubMed ID: 17847935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
    Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
    APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection and treatment of ductal carcinoma of the breast].
    Semiglazov VV; Tabagua TT; Matsko DE
    Vopr Onkol; 2011; 57(6):699-701. PubMed ID: 22416383
    [No Abstract]   [Full Text] [Related]  

  • 12. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation.
    Haffty BG; Yang Q; Moran MS; Tan AR; Reiss M
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(4):1006-13. PubMed ID: 18262731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Menopausal hormone therapy and breast cancer phenotype: does dose matter?
    Garwood ER; Kumar AS; Shim V
    Ann Surg Oncol; 2008 Sep; 15(9):2526-32. PubMed ID: 18618187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
    Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
    Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of prostate cancer in male breast cancer patients: a risk factor for prostate cancer screening.
    Lee UJ; Jones JS
    Prostate Cancer Prostatic Dis; 2009; 12(1):52-6. PubMed ID: 18504455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does estrogen receptor negative/progesterone receptor positive breast carcinoma exist?
    De Maeyer L; Van Limbergen E; De Nys K; Moerman P; Pochet N; Hendrickx W; Wildiers H; Paridaens R; Smeets A; Christiaens MR; Vergote I; Leunen K; Amant F; Neven P
    J Clin Oncol; 2008 Jan; 26(2):335-6; author reply 336-8. PubMed ID: 18182677
    [No Abstract]   [Full Text] [Related]  

  • 17. Receptor status and ethnicity of indigent patients with breast cancer in New York City.
    Marti JL; Guth A; Naik A; Hiotis KL
    Arch Surg; 2008 Dec; 143(12):1227-30. PubMed ID: 19075177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer.
    Woo SU; Bae JW; Kim CH; Lee JB; Koo BW
    Ann Surg Oncol; 2008 Jan; 15(1):281-5. PubMed ID: 17763975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute risk models for subtypes of breast cancer.
    Gail MH; Anderson WF; Garcia-Closas M; Sherman ME
    J Natl Cancer Inst; 2007 Nov; 99(22):1657-9. PubMed ID: 18000214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.